Daniel Kohane, MD
Interventional Pain Medicine · Babylon, NYNPI 1235399734
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $19,080 of the $26,629 with a category attached, or 71.7%. 60 manufacturers reported payments, led by International Rehabilitative Sciences, Inc at 26.9% of the total. Reporting peaked in 2024 at $9,797 and has fallen 68.9% since, to $3,047 in 2025.
Across 1,303 payments — averaging $20.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- International Rehabilitative Sciences, Inc$7K
- Collegium Pharmaceutical, Inc.$2K
- Boston Scientific$2K
- Abbott$2K
- AbbVie$1K
- Medtronic$952
- plus $11K from 54 others
What the payments were for
- Travel & lodging$3261%
- Food & beverage$19,08072%
- Education$580%
- Other$7,16427%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RS 4i Plus Sequential Stimulator$7,164
- RS-LBG, RS-FBG$7,164
- Intracept$1,228
- Prolate$843
- Evoke$323
- Axium$317
- Nalu Neurostimulation System$243
- Nalocet$211
- Proclaim IPG$145
- mild Device Kit$135
- GENERAL PAIN MANAGEMENT$126
- ReActiv8$111
- Penta SCS Leads$106
- PROCLAIM$101
How this compares
$26,629 in reported general payments places this provider in the 85th percentile of 132 interventional pain medicine providers in New York.
See all interventional pain medicine providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 453 | $39,621 |
| Xtampza ErOxycodone Myristate | 47 | $31,806 |
| ProlateOxycodone Hcl/Acetaminophen | 19 | $13,796 |
| BelbucaBuprenorphine Hcl | 16 | $11,748 |
| Diclofenac Sodium | 60 | $7,085 |
| Lidocaine | 56 | $6,591 |
| Hysingla ErHydrocodone Bitartrate | 15 | $5,747 |
| MovantikNaloxegol Oxalate | 11 | $5,209 |
| Pregabalin | 116 | $3,516 |
| Fentanyl | 18 | $3,236 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 146 | $2,967 |
| Gabapentin | 220 | $2,229 |
| Oxycodone Hcl | 81 | $1,175 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 54 | $1,003 |
| Morphine Sulfate ErMorphine Sulfate | 40 | $848 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca | $2,299 | $43,55463 claims |
| Forte Bio-pharma LLCProlate | $727 | $13,79619 claims |
| Redhill Biopharma Inc.Movantik | $121 | $5,20911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 132 interventional pain medicine providers in New York.
Other interventional pain medicine in Babylon
- Luis FandosBabylon$32K
- Jonathan FinkelsteinBabylon$11K
- Sunil AlbertBabylon$10K
- Corey HunterNew York$446K
- Neel MehtaNew York$432K
- Hemant KaliaRochester$179K
- Martin FerrilloAlbany$164K
- George ChaseKew Gardens$102K
- Kimberly SackheimNew York$102K
- Suelane OuroNew York$68K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.